VTE Prevention After Hip or Knee Replacement
|
|
- Gervais Booker
- 5 years ago
- Views:
Transcription
1 This Clinical Resource gives subscribers additional insight related to the Recommendations published in May 2018 ~ Resource # VTE Prevention After Hip or Knee Replacement The American College of Chest Physicians (ACCP) 2012 guidelines recommend over other anticoagulants for VTE prophylaxis in hip or knee arthroplasty. 12 The American Academy of Orthopaedic Surgeons and Thrombosis Canada do not cite a preference. 14,18 The chart below compares alternatives in regard to efficacy and bleeding risk, and provides dosing guidance. Choice should be individualized, taking into account patient VTE risk factors and bleeding risk. 15 ACCP suggests prophylaxis for up to 35 days (minimum 10 to 14 days), while Thrombosis Canada recommends 14 to 35 days, depending on patient risk. 12,14 However, product labeling is more specific, and is based on durations used in the clinical trials. --Information in table may differ from product labeling.-- Abbreviations: HIT = heparin-induced thrombocytopenia; = low-molecular-weight heparin; SC = subcutaneous Alternatives to Drug Dose/Duration Efficacy vs Bleeding Risk vs When to Consider Apixaban (Eliquis) (See footnote a ) 2.5 mg twice daily x 35 days (hip [Canada: 32 to 38 days]) or 12 days (knee [Canada: 10 to 14 days]) starting 12 to 24 hrs post-op (Canada: if hemostasis achieved). 1,2 Some experts recommend starting 18 to 24 hrs post-op due to bleeding risk. 15 Similar for VTE prevention [Evidence level A-1]. 3,4 Similar major or clinically relevant nonmajor bleeding (combined endpoint) [Evidence level A-1]. 3,4 When an oral option is desired, or patient has history of HIT. Aspirin Dabigatran (Pradaxa) 162 mg once daily for at least 10 to 14 days, up to 35,16 (See information below regarding aspirin use after 5 days of rivaroxaban.) 220 mg once daily x 28 to 35 days (hip) or 10 days (knee [Canada]). If started on day of surgery (1 to 4 hrs post-op, assuming hemostasis achieved), initial dose is 110 mg. 5,6 Some experts recommend starting 18 to 24 hrs post-op due to bleeding risk fewer VTEs compared to per 1,000 patients treated for up to Similar for combined endpoint of VTE and mortality [Evidence level A-1]. 7-9 No proof bleeding risk is lower. 12 Similar major bleeding [Evidence level A-1]. 7-9 If patient would not otherwise get VTE prophylaxis. 17 Not an option per Thrombosis Canada. 14 One ACCP member felt aspirin monotherapy should not be an option. 12 When an oral option is desired.
2 (Clinical Resource #340506: Page 2 of 5) Drug Fondaparinux (Arixtra, generics) Heparin, unfractionated Rivaroxaban (Xarelto) Rivaroxaban, followed by aspirin Dose/Duration (See footnote a ) 2.5 mg SC once daily starting 6 to 8 hours postop, for up to 11 days (Canada: up to one month). 20,21 Caution in severe renal impairment or weight <50 kg. 21 Contraindicated per U.S. labeling. 20 5,000 units SC q 8 to q 12 hrs, starting 1 to 2 hours pre-op. 12,19,22 Follow general guideline recommendations (see above) for duration of therapy. 10 mg once daily for 35 days (hip) or 12 days (knee [Canada: 14 days]) starting 6 to 10 hrs post-op, assuming hemostasis achieved. 10,11 Some experts recommend starting 18 to 24 hrs post-op due to bleeding risk. 15 Rivaroxaban 10 mg once daily for 5 days, then aspirin 81 mg once daily for 9 days (knee) or 30 days (hip). 13 Warfarin Dose to achieve target INR of 2 to Pneumatic compression Follow general guideline recommendations (see above) for duration of therapy. 18 hours per day for at least 10 to 14 days. Use of a device capable of recording wear-time is recommended. 12 Consider use with pharmacologic prophylaxis during hospital stay. 12 Efficacy vs 3 fewer VTEs per 3 fewer VTEs per Higher. Prevents 4 more VTEs per N/A. Similar to rivaroxaban for symptomatic VTE [Evidence level A-1] fewer VTEs per fewer VTEs per 14 Bleeding Risk vs Higher. Nine more major, nonfatal bleeds, or bleeds requiring reoperation per 1,000 patients Similar. 12 Higher. Nine more serious bleeds per 1,000 patients N/A. Similar to rivaroxaban for major and clinically important bleeding [Evidence level A-1]. 13 Lower. Four fewer major bleeding events per 1,000 patients But risk may be higher than with extended prophylaxis. 12 Lower. Ten fewer major bleeds per 14 When to Consider An injectable alternative when formulary issues or a history of HIT preclude use of. 12 An injectable alternative when cost is an issue. Not an option per Thrombosis Canada. 14 When an oral option is desired. When an oral option is desired and patient is not at high VTE risk 14 (e.g., metastatic cancer, history of VTE). 13,18 When an oral option with ability to monitor anticoagulant effect is desired. Patient at high risk of bleeding 14,18 (e.g., bleeding disorder, liver disease). 18 Patent who places high value on avoiding bleeding and low value on inconvenience. 12
3 (Clinical Resource #340506: Page 3 of 5) Drug Enoxaparin (Lovenox, generics) Dalteparin (Fragmin) Usual Dose/Duration (See footnote b ) 30 mg SC q 12 h starting 12 to 24 hrs post-op, assuming hemostasis achieved (hip or knee) for 7 to 14 days, 23,24 or 40 mg SC once daily (hip) starting 9 to 15 hrs pre-op, for 7 to14 days. 14,23,c Renal dosing: CrCl <30 ml/min: 30 mg SC once daily. 23,24 Post-op start: 2,500 units SC 4 to 8 hours post-op (assuming hemostasis achieved), then 5,000 units SC once daily (starting at least 6 hrs after the previous dose). 25,26,c Pre-op start, day of surgery: 2,500 units SC within 2 hrs pre-op followed by 2,500 units SC 4 to 8 hrs post-op (assuming hemostasis achieved), then 5,000 IU SC once daily (starting at least 6 hrs after the previous dose). 25,26,c Pre-op start, evening before surgery: 5,000 units SC 10 to 14 hrs pre-op, then 5,000 units SC once daily starting 4 to 8 hrs post-op (and about 24 hrs after the first dose), assuming hemostasis achieved. 25,26,c Duration: 5 days minimum 25,26 Not FDA- or Health Canada-approved for VTE prophylaxis after knee replacement. 25,26,c Renal dosing: Consider dose reduction (Canadian labeling) or monitor factor Xa levels (U.S. labeling) in patients with severe renal impairment (CrCl <30 ml/min). 25,26 Nadroparin (Fraxiparine) (Canada) 38 U/kg SC once daily on post-op days 1 to 3 (1,900 units if <50 kg, 2,850 units if 50 to 69 kg, 3,800 units if 70 kg), followed by 57 U/kg SC once daily (2,850 units if <50 kg, 3,800 units if 50 to 69 kg, 5,700 units if 70 kg) on day 4 onward. May start 12 hrs preop, with second dose 12 hrs post-op. 27,c Minimum duration 10 days. 27 Tinzaparin (Innohep, Canada) Renal dosing: Contraindicated if CrCl <30 ml/min. Consider reduced dose for CrCl 30 to 50 ml/min. 27 4,500 U 14 or 75 U/kg SC once daily post-op for 7 to 10 days. 28,c For hip surgery, may give 50 units/kg once daily starting 2 hrs preop. 28,c Renal dosing: Use caution and consider dose reduction if CrCl <30 ml/min. 28 a. See our chart, Comparison of Oral Anticoagulants, for dosing in special populations (e.g., renal or hepatic impairment, elderly, low body weight). Consult product labeling regarding initiation in patients with perioperative epidural/spinal anesthesia. b. See our chart, Dosing in Special Populations, for more dosing and monitoring considerations in obesity, pregnancy, renal impairment, and underweight/frail patients. c. ACCP guidelines recommend starting 12 hrs pre-op or 12 hrs post-op. 12 Users of this resource are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national organizations. Information and internet links in this article were current as of the date of publication.
4 (Clinical Resource #340506: Page 4 of 5) Levels of Evidence In accordance with our goal of providing Evidence- Based information, we are citing the LEVEL OF EVIDENCE for the clinical recommendations we publish. Level Definition Study Quality A B C Good-quality patient-oriented evidence.* Inconsistent or limited-quality patient-oriented evidence.* 1. High-quality RCT 2. SR/Meta-analysis of RCTs with consistent findings 3. All-or-none study 1. Lower-quality RCT 2. SR/Meta-analysis with low-quality clinical trials or of studies with inconsistent findings 3. Cohort study 4. Case control study Consensus; usual practice; expert opinion; disease-oriented evidence (e.g., physiologic or surrogate endpoints); case series for studies of diagnosis, treatment, prevention, or screening. *Outcomes that matter to patients (e.g., morbidity, mortality, symptom improvement, quality of life). RCT = randomized controlled trial; SR = systematic review [Adapted from Ebell MH, Siwek J, Weiss BD, et al. Strength of Recommendation Taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. Am Fam Physician 2004;69: Project Leader in preparation of this clinical resource (340506): Melanie Cupp, Pharm.D., BCPS References 1. Product information for Eliquis. Pfizer. New York, NY February Product monograph for Eliquis. Pfizer Canada. Kirkland, QC H9J 2M5. April Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010;363: Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised doubleblind trial. Lancet 2010;375: Product information for Pradaxa. Boehringer Ingelheim Pharmaceuticals. March Product monograph for Pradaxa. Boehringer Ingelheim Canada. Burlington, ON L7L 5H4. August The RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24(1): Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, noninferiority trial. Lancet 2007;370: Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5: Product information for Xarelto. Janssen Pharmaceuticals. Titusville, NJ October Product monograph for Xarelto. Bayer. Mississauga, ON L4W 5R6. February Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(Suppl 2):e278S-e325S. 13. Anderson DR, Dunbar M, Murnaghan J, et al. Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. N Engl J Med 2018;378: Thrombosis Canada. Thromboprophylaxis: orthopedic surgery content/uploads/2018/03/thromboprophylaxis- Orthopedic-2018Feb21-Final.pdf. (Accessed April 3, 2018). 15. Lieberman JR, Heckman N. Venous thromboembolism prophylaxis in total hip arthroplasty and total knee arthroplasty patients: from guidelines to practice. J Am Acad Orthop Surg 2017;25: No authors listed. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000;355: PL Voices, Aspirin for Prevention of Thrombosis. Pharmacist s Letter/Prescriber s Letter. March Jacobs JJ, Mont MA, Bozic KJ, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Bone Joint Surg Am 2012;94: American Academy of Orthopaedic Surgeons. Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. Evidence-based guideline and evidence report ull_guideline.pdf. (Accessed April 4, 2018). 20. Product information for Arixtra. Mylan Institutional. Rockford, IL August Product monograph for Arixtra. Aspen Pharmacare Canada. Toronto, ON M5C 1S2. April 2017.
5 (Clinical Resource #340506: Page 5 of 5) 22. Clinical Pharmacology powered by Clinical Key. Tampa (FL): Elsevier (Accessed April 4, 2018). 23. Product information for Lovenox. Sanofi-Aventis U.S. Bridgewater, NJ October Product monograph for Lovenox. Sanofi-Aventis Canada. Laval, QC H7V 0A3. June Product information for Fragmin. Pfizer Labs. New York, NY June Product monograph for Fragmin. Pfizer Canada. Kirkland, QC H9J 2M5. September Product monograph for Fraxiparine. Aspen Pharmacare Canada. Toronto, ON M5C 1S2. December Product monograph for Innohep. Leo Pharma. Thornhill, ON L3T 7W8. May Cite this document as follows: Clinical Resource, VTE Prevention After Hip or Knee Replacement. Pharmacist s Letter/Prescriber s Letter. May Evidence and Recommendations You Can Trust 3120 West March Lane, Stockton, CA ~ TEL (209) ~ FAX (209) Copyright 2018 by Therapeutic Research Center Subscribers to the Letter can get clinical resources, like this one, on any topic covered in any issue by going to PharmacistsLetter.com, PrescribersLetter.com, PharmacyTechniciansLetter.com, or NursesLetter.com
Oral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationTHROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY
THROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY OBJECTIVE: To outline a practical approach for the prevention of venous thromboembolism (VTE) in patients undergoing non-orthopedic surgery. BACKGROUND: VTE is
More informationAspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty: The EPCAT II Trial
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty: The EPCAT II Trial Wednesday, June 6, 2018, 2:00PM ET Guest Author: David R. Anderson, MD Presenter: Sara Vazquez, PharmD Moderators:
More informationOutpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 General Principles: There is compelling data in the medical literature to support
More informationObjectives. Venous Thromboembolism (VTE) Prophylaxis. Case VTE WHY DO IT? Question: Who Is At Risk?
Objectives Venous Thromboembolism (VTE) Prophylaxis Rishi Garg, MD Department of Medicine Identify patients at risk for VTE Options for VTE prophylaxis Current Recommendations (based on The Seventh ACCP
More informationDVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
More informationVenous Thromboembolism Prophylaxis: Checked!
Venous Thromboembolism Prophylaxis: Checked! William Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University of Toronto National Lead, VTE Prevention, Safer
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationClinical Policy: Dabigatran (Pradaxa) Reference Number: CP.PMN.49 Effective Date: Last Review Date: 05.18
Clinical Policy: (Pradaxa) Reference Number: CP.PMN.49 Effective Date: 05.01.12 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationPradaxa (dabigatran)
Pradaxa (dabigatran) Policy Number: 5.01.574 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Pradaxa
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
Types of Insulin Rapid-acting insulin: lispro (Humalog), aspart (NovoRapid), glulisine (Apidra) Regular short-acting insulin: Humulin R, Novolin ge Toronto, Hypurin Regular Basal insulin: NPH (Humulin
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationGetting Started Kit VENOUS THROMBOEMBOLISM PREVENTION. Section 2: Evidence-Based Appropriate VTE Prophylaxis
Reducing Harm Improving Healthcare Protecting Canadians VENOUS THROMBOEMBOLISM PREVENTION Getting Started Kit Section 2: Evidence-Based Appropriate VTE Prophylaxis January 2017 www.patientsafetyinstitute.ca
More informationAspirin as Venous Thromboprophylaxis
Canadian Society of Internal Medicine Nov 2, 2017 Aspirin as Venous Thromboprophylaxis Bill Geerts, MD, FRCPC Thromboembolism Consultant, Sunnybrook HSC Professor of Medicine, University of Toronto Disclosures
More informationEarly Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement. Marilyn Szekendi, PhD, RN
Early Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement Marilyn Szekendi, PhD, RN ANA 7 th Annual Nursing Quality Conference, February 2013 Research Team Banafsheh Sadeghi,
More informationFactor Xa Inhibition in the Management of Venous Thromboembolism: Important Safety Information. Important Safety Information (cont d)
Factor Xa Inhibition in the Management of Venous Thromboembolism: The Role of Fondaparinux WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with
More informationChange from lovenox to pradaxa
P ford residence southampton, ny Change from lovenox to pradaxa 14-11-2017 We wanted to put out a friendly reminder that the Ask 3 Teach 3 (A3T3) initiative is indeed full swing. This is an multidisciplinary
More informationSlide 1. Slide 2. Slide 3. Outline of This Presentation
Slide 1 Current Approaches to Venous Thromboembolism Prevention in Orthopedic Patients Hujefa Vora, MD Maria Fox, RN June 9, 2017 Slide 2 Slide 3 Outline of This Presentation Pathophysiology of venous
More informationClinical Guideline for Anticoagulation in VTE
Clinical Guideline for Anticoagulation in VTE These clinical guidelines are intended to provide evidence-based recommendations regarding the anticoagulation in patients with DVT and PE. Please note that
More information10/8/2012. Disclosures. Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines. Goals and Objectives. Outline
Disclosures Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines No relevant conflicts of interest related to the topic presented. Cyndy Brocklebank, PharmD, CDE Chronic Disease Management
More informationCase presentation: A 69-year-old
CLINICIAN UPDATE Prevention of Venous Thromboembolism in Total Knee and Hip Replacement David Warwick, MD, FRCS, FRCS(Orth) Case presentation: A 69-year-old woman had a cemented hip replacement 15 years
More informationDrug Class Review Newer Oral Anticoagulant Drugs
Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationPULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT
PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT OBJECTIVE: To provide a diagnostic algorithm and treatment options for patients with acute pulmonary embolism (PE). BACKGROUND: Venous thromboembolism (VTE)
More informationPRIMARY TOTAL KNEE & HIP
Clinical Guideline Version 2.0 Title: PRIMARY TOTAL KNEE & HIP Venous ThromboEmbolic (VTE) Guideline Target Audience: thopedic Surgeons and their Advanced Practice Practitioner partners; Hospitalists,
More informationUpdates in Management of Venous Thromboembolic Disease
Updates in Management of Venous Thromboembolic Disease November 7 th 2018 UHN Emergency Conference Susan Jenkins RN(EC) NP-Adult Thrombosis and Hemostasis Program University Health Network Disclosures
More informationNOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
TITLE VENOUS THROMBOEMBOLISM PROPHYLAXIS SCOPE Provincial Acute and Sub-Acute Care Facilities APPROVAL AUTHORITY Alberta Health Services Executive Committee SPONSOR Vice President, Quality and Chief Medical
More informationMisunderstandings of Venous thromboembolism prophylaxis
Misunderstandings of Venous thromboembolism prophylaxis Veerendra Chadachan Senior Consultant Dept of General Medicine (Vascular Medicine and Hypertension) Tan Tock Seng Hospital, Singapore Case scenario
More informationNational Institute for Health and Clinical Excellence Health Technology Appraisal
National Institute for Health and Clinical Excellence Health Technology Appraisal Rivaroxaban for the prevention of venous thromboembolism after elective orthopaedic surgery of the lower limbs Comment
More informationProstate Biopsy Alerts
Prostate Biopsy Alerts Saskatchewan Prostate Assessment Pathway Guidelines for the Primary Care Provider for Patient Preparation and the Management of Medications and Complications September 2016 Table
More informationPostsurgical Home Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Clinical Position Statement Postsurgical Home Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis Effective: October 2017 Next Review: September 2018 CLINICAL POSITION STATEMENT Postsurgical
More informationVenous Thromboembolism Prophylaxis After Major Orthopaedic Surgery: A Pooled Analysis of Randomized Controlled Trials
Winner of the AAHKS Award Venous Thromboembolism Prophylaxis After Major Orthopaedic Surgery: A Pooled Analysis of Randomized Controlled Trials Greg A. Brown, MD, PhD The Journal of Arthroplasty Vol. 24
More informationVenous Thromboembolism National Hospital Inpatient Quality Measures
Venous Thromboembolism National Hospital Inpatient Quality Measures Presentation Overview Review venous thromboembolism as a new mandatory measure set Outline measures with exclusions and documentation
More informationDrug Use Criteria: Direct Oral Anticoagulants
Texas Vendor Drug Program Drug Use Criteria: Oral Anticoagulants Publication History 1. Developed March 2017. 2. Revised February 2018. Notes: Information on indications for use or diagnosis is assumed
More informationTRANSPARENCY COMMITTEE OPINION. 18 April 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 April 2007 ARIXTRA 2.5 mg/0.5 ml, solution for injection in prefilled syringe Pack of 2 (CIP: 359 225-4) Pack of
More informationVenothromboembolism prophylaxis: Trauma and Orthopaedics Clinical guideline, V2
Clinical Guideline Venothromboembolism prophylaxis: Trauma and Orthopaedics 11/11/11 TEMPORARY GUIDANCE There is no prophylactic tinzaparin available in the Trust currently. Please substitute enoxaparin
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationDisclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose
Disclosures No financial conflicts of interest to disclose The Perioperative Management of Anticoagulants Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical
More informationTitle: Low Molecular Weight Heparins (LMWH), fondaparinux (Arixtra)
Origination: 03/29/05 Revised: 09/01/10 Annual Review: 11/20/13 Purpose: To provide guidelines and criteria for the review and decision determination of requests for medications that requires prior authorization.
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Oral Anticoagulants Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Oral Anticoagulant - Bevyxxa (betrixaban), Eliquis (apixaban), Pradaxa (dabigatran),
More informationWMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT
WMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT - Entering orders for anticoagulation in Cerner Providers will enter individual orders (oneoffs)
More informationPost-procedure dose ok after hours. 12 hours (q 24h dosing only) assuming surgical hemostasis; second dose 24 hours after first dose.
Medication Time to wait after last dose Post-procedure dose ok after hours Can pull catheter hours after last dose Can give next dose hours after pulling catheter Enoxaparin (Lovenox) Prophylactic dose
More informationVenous thromboembolism after total knee replacement or total hip replacement: what can be learnt from root-cause analysis?
TRAUMA AND ORTHOPAEDIC SURGERY Ann R Coll Surg Engl 2016; 98: 538 542 doi 10.1308/rcsann.2016.0202 Venous thromboembolism after total knee replacement or total hip replacement: what can be learnt from
More informationXarelto (rivaroxaban)
Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationincidence of cancer-associated thrombosis (CAT) is further increased by additional risk factors such as chemotherapeutic 2
CANCER ASSOCIATED THROMBOSIS TREATMENT Patients with cancer are at a greater risk of developing venous thromboembolism than non-cancer patients, partly due to the ability of tumour cells to activate the
More informationAnticoagulation for prevention of venous thromboembolism
Anticoagulation for prevention of venous thromboembolism Original article by: Michael Tam Note: updated in June 2009 with the eighth edition (from the seventh) evidence-based clinical practice guidelines
More informationINDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY
INDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY N.E. Pearce INTRODUCTION Preventable death Cause of morbidity and mortality Risk factors Pulmonary embolism
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationProtocol. Postsurgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Postsurgical Outpatient Use of Limb Compression Devices for (10128) (Formerly Outpatient Use of Limb Pneumatic Compression Devices for ) Medical Benefit Effective Date: 07/01/14 Next Review Date: 03/15
More informationPrimary VTE Thromboprophylaxis
Primary VTE Thromboprophylaxis Controversies in Hematology 53 rd Annual Meeting of Thai Society of Hematology Bundarika Suwanawiboon, MD Division of Hematology Department of Medicine Faculty of Medicine
More informationThese are guidelines only and can be deviated from if it is thought to be in the patient s best interest.
Clinical Guideline Venothromboembolism prophylaxis: Trauma and Orthopaedics Venous thromboembolism (VTE) is a recognised complication associated with inactivity and surgical procedures. Therefore, all
More informationDeep vein thrombosis: diagnosis, prevention and treatment
Deep vein thrombosis: diagnosis, prevention and treatment Catherine Bagot BSc, MD, MRCP, FRCPath and Campbell Tait BSc, FRCP, FRCPath Deep vein thrombosis can lead to significant morbidity and has well-recognised
More informationPage: 1 of 13. Post-Surgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Last Review Status/Date: March 2014 Page: 1 of 13 Compression Devices for Venous Description Patients undergoing major orthopedic surgery are at increased risk for venous thromboembolism (VTE). Patients
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationPage: 1 of 14. Post-Surgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Subject: Post-Surgical Outpatient Use of Limb Page: 1 of 14 Last Review Status/Date: March 2015 Post-Surgical Outpatient Use of Limb Compression Devices for Venous Description Patients undergoing major
More informationVenous Thromboembolism Prophylaxis
Approved by: Venous Thromboembolism Prophylaxis Vice President and Chief Medical Officer; and Vice President and Chief Operating Officer Corporate Policy & Procedures Manual Number: Date Approved January
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationNanik Hatsakorzian Pharm.D/MPH
Pharm.D/MPH 2014 1 Therapeutics FDA indication & Dosing Clinical Pearls Anticoagulants Heparin Antiphospholipid antibody syndrome Cerebral thromboembolism Prosthetic heart valve Acute coronary syndrome
More informationEXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS
EXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS Samuel Z. Goldhaber, MD Director, VTE Research Group Cardiovascular Division Brigham and Women s Hospital Professor of Medicine Harvard Medical
More informationTechnology appraisal guidance Published: 25 January 2012 nice.org.uk/guidance/ta245
Apixaban for the prevention ention of venous thromboembolism after total hip or knee replacement in adults Technology appraisal guidance Published: 25 January 2012 nice.org.uk/guidance/ta245 NICE 2018.
More informationTreatment Options and How They Work
Treatment Options and How They Work Robin Offord Director of Clinical Pharmacy UCL Hospitals NHS Foundation Trust robin.offord@uclh.nhs.uk Introducing the term anticoagulant... What they do Inhibit the
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More informationPerioperative Management of the Anticoagulated Patient
Perioperative Management of the Anticoagulated Patient Citywide Resident Perioperative Medical Consultation Conference 5/5/17 Matthew Eisen, MD Director, Anticoagulation Services MetroHealth Medical Center
More informationADVANCES IN HEMATOLOGY
ADVANCES IN HEMATOLOGY Current Developments in the Management of Hematologic Disorders Section Editor: Craig M. Kessler, MD Are Direct Acting Oral Anticoagulants Ready for Prime-Time Use in Cancer-Related
More informationThromboembolism and cancer: New practices. Marc Carrier
Thromboembolism and cancer: New practices Marc Carrier Marc Carrier Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board Leo Pharma, BMS No relevant
More informationFatal P.E. Historic 1-2% Current %
Dr. (Prof.) Anil Arora MS (Ortho) DNB (Ortho) Dip SIROT (USA) FAPOA (Korea), FIGOF (Germany), FJOA (Japan) Commonwealth Fellow Joint Replacement (Royal National Orthopaedic Hospital, London, UK) Senior
More informationObesity, renal failure, HIT: which anticoagulant to use?
Obesity, renal failure, HIT: which anticoagulant to use? Mark Crowther with thanks to Dr David Garcia and others. This Photo by Unknown Author is licensed under CC BY-SA 1 2 Drug choices The DOACs have
More informationOriginal Policy Date
MP 5.01.15 Newer Oral Anticoagulants Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Created with literature search/12:2013 Return to Medical
More informationGuidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban
Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Purpose The aim of this guidance is to outline the management of patients presenting
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationNOAC s across indications
Sektion CAMPUS INNENSTADT Med. Klinik und Poliklinik IV NOAC s across indications Ulrich Hoffmann, M.D. Division of Vascular Medicine University Hospital Munich, Germany Disclosure Speaker name: Ulrich
More informationLovenox to xarelto The Borg System is 100 % Retrievable & Reusable Lovenox to xarelto
Lovenox to xarelto The Borg System is 100 % Lovenox to xarelto Background: I got a DVT in my left calf after my fifth knee surgery. I'm a 32yo healthy, competitive athlete and have never had any healthy
More informationDirect Oral Anticoagulants
Direct Oral Anticoagulants Holly Jahn, PharmD, CACP Objectives Identify the FDA approved indications for use, appropriate dosing, and monitoring parameters for each direct oral anticoagulant. Distinguish
More informationPerioperative VTE Prophylaxis
Perioperative VTE Prophylaxis Gregory J. Misky, M.D. Assistant Professor of Medicine University Of Colorado Denver You recommend the following 72 y.o. man admitted for an elective R hip repair. Patient
More informationComparison of novel oral anticoagulants (NOACs)
Comparison of novel oral anticoagulants (NOACs) For guidance for full information refer to individual SPCs available at www.medicines.org.uk Licensed indications for NOACs Prevention of stroke and systemic
More informationAre guidelines for anticoagulation useful in cancer patients?
Session 3 Striking a Balance Between Bleeding and the Risk of Thrombosis in Cancer Patients Are guidelines for anticoagulation useful in cancer patients? Sebastian Szmit Department of Pulmonary Circulation
More informationInhaled Corticosteroid Dose Comparison in Asthma
This Clinical Resource gives subscribers additional insight related to the Recommendations published in April 2017 ~ Resource #330402 Inhaled Corticosteroid Dose Comparison in Asthma The chart below provides
More informationMeasure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)
Measure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) 2013 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage
More information1/27/2016. Disclosure. Goals. The Risk and Prevention of Venous Thromboembolism (VTE) in Patients With Foot and Ankle Pathology
The Risk and Prevention of Venous Thromboembolism (VTE) in Patients With Foot and Ankle Pathology STEVEN STEINLAUF, MD THE ORTHOPAEDIC FOOT AND ANKLE INSTITUTE OF SOUTH FLORIDA CLINICAL ASSISTANT PROFESSOR
More informationNew Horizons in Anticoagulation: The Way of the Future. Disclosure. Outline. The speaker has nothing to disclose in relation to this presentation
New Horizons in Anticoagulation: The Way of the Future Gloria Grice Pharm.D., BCPS St. Louis College of Pharmacy & Barnes-Jewish Hospital Anticoagulation Service Disclosure The speaker has nothing to disclose
More informationVenous Thromboembolism. Prevention
Venous Thromboembolism Prevention August 2010 Venous Thromboembloism Prevention 1 1 Expected Practice Assess all patients upon admission to the ICU for risk factors of venous thromboembolism (VTE) and
More informationPatients with cancer are at a greater risk of developing venous thromboembolism than non-cancer patients, partly due to the 1
CANCER ASSOCIATED THROMBOSIS TREATMENT Patients with cancer are at a greater risk of developing venous thromboembolism than non-cancer patients, partly due to the 1 ability of tumour cells to activate
More informationVenous Thromboembolism Prophylaxis - Why Should We Care? Harry Gibbs FRACP FCSANZ Vascular Physician The Alfred Hospital
Venous Thromboembolism Prophylaxis - Why Should We Care? Harry Gibbs FRACP FCSANZ Vascular Physician The Alfred Hospital VTE is common and dangerous 5 VTE is Common VTE Incidence: 1.5 / 1000 per year
More informationAbstract. Background. Methods
Abstract Background Malignancy is a major risk factor for developing venous thromboembolism (VTE), and thus cancer patients are at high risk for deep vein thrombosis (DVT) and/or pulmonary embolism (PE).
More informationTHROMBOPROPHYLAXIS IN ORTHOPAEDIC SURGERY. Title of Guideline. (Governance) Version Number 1 Date of Review October 17
Title of Guideline THROMBOPROPHYLAXIS IN ORTHOPAEDIC SURGERY Contact Name and Job Title (Author) Gary Masterman Deputy Chief Pharmacist (Governance) Division & Specialty Specialist Services Guideline Number
More informationCharacteristics of Transdermal Patches
This Clinical Resource gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER July 2017 ~ Resource #330733 Characteristics of Transdermal
More informationWhen and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD
When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD December 12, 2015 Disclosures CONSULTANT Merck; New Haven
More informationMedical Patients: A Population at Risk
Case Vignette A 68-year-old woman with obesity was admitted to the Medical Service with COPD and pneumonia and was treated with oral corticosteroids, bronchodilators, and antibiotics. She responded well
More informationLeading the Charge in Anticoagulation Reversal: Benefits, Risks, and Key Factors in Application to the Traumatically Injured Patient
Leading the Charge in Anticoagulation Reversal: Benefits, Risks, and Key Factors in Application to the Traumatically Injured Patient Emily Hutchison, PharmD BCPS Clinical Pharmacy Specialist, Trauma/Adult
More informationDENOMINATOR: All surgical patients aged 18 years and older undergoing procedures for which VTE prophylaxis is indicated in all patients
Measure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2017 OPTIONS FOR INDIVIDUAL MEASURES:
More informationThe clinical relevance of AMPLIFY programme
Venice October 16th 2015 The clinical relevance of AMPLIFY programme Francesco Dentali Department of Clinical Medicine Insubria University Varese Disclosures Bayer Bristol-Myers Squibb/Pfizer Boehringer
More informationUpdate with the New Oral Anticoagulants: Today s Issues for the Front Line Pharmacist
Update with the New Oral Anticoagulants: Today s Issues for the Front Line Pharmacist Peter Thomson, Pharm D. Clinical Resource Pharmacist, Medicine Program Winnipeg Regional Health Authority Clinical
More informationNew Oral Anticoagulant Drugs in the Prevention of DVT
New Oral Anticoagulant Drugs in the Prevention of DVT Targets for Anticoagulants ORAL DIRECT VKAs inhibit the hepatic synthesis of several coagulation factors Rivaroxaban Apixaban Edoxaban Betrixaban X
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 15 May 2013 ARIXTRA 2.5 mg/0.5 ml, solution for injection in pre-filled syringe B/2 (CIP: 34009 359 225 4 0) B/7 (CIP:
More informationABSTRACT INTRODUCTION
Adv Ther (2014) 31:473 493 DOI 10.1007/s12325-014-0119-7 REVIEW Phase III Trials of New Oral Anticoagulants in the Acute Treatment and Secondary Prevention of VTE: Comparison and Critique of Study Methodology
More information